Literature DB >> 1740581

The effect of aerosol distribution on airway responsiveness to inhaled methacholine in patients with asthma.

B L Laube1, P S Norman, G K Adams.   

Abstract

It has been demonstrated that airway deposition of inhaled aerosols is more heterogeneous in patients with asthma than in normal subjects. Nevertheless, the influence of abnormal airway deposition on responses to bronchoactive aerosols is poorly understood. We altered bronchopulmonary deposition heterogeneity of methacholine aerosol in nine asymptomatic patients with asthma by controlling inspiratory flow at high (approximately 60 L/min) versus low (approximately 12 L/min) rates on 2 study days and determined the effect on the provocative dose of methacholine causing a 20% fall in FEV1 (PD20) (often used as a measure of airway responsiveness). Deposition uniformity was quantified from gamma-camera scans of the lungs in terms of the distribution of a technetium-labeled aerosol that was inhaled rapidly or slowly before the inhalation of methacholine. Increased deposition in an inner (large, central airways) versus an outer (peripheral airways and alveoli) zone of the right lung (inner/outer ratio, greater than 1) and higher values of skew (an index of deposition asymmetry) and kurtosis (an index of deposition range) indicated enhanced heterogeneity of deposition. Mean (+/- SD) inner/outer ratio was significantly higher during rapid inspiration compared to slow inspiration with 2.91 +/- 0.51 and 1.84 +/- 0.30, respectively (p less than 0.01). Mean skew and kurtosis were also significantly higher after rapid inspiration, with 1.12 +/- 0.35 and 3.86 +/- 1.25, respectively, compared to 0.74 +/- 0.36 and 2.64 +/- 0.77 after slow inhalation (p less than 0.01). Geometric mean PD20 methacholine was significantly reduced when the aerosol was inhaled rapidly, with 5.9 cumulative methacholine units compared to 15.7 units after slow inhalation (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1740581     DOI: 10.1016/0091-6749(92)90317-u

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

1.  Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.

Authors:  Beth L Laube; Kathryn A Carson; Gail Sharpless; Laura M Paulin; Nadia N Hansel
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-04-08       Impact factor: 2.849

Review 2.  The science of nebulised drug delivery.

Authors:  C O'Callaghan; P W Barry
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

3.  Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis.

Authors:  Beth L Laube; Gail Sharpless; Kathryn A Carson; Amber Kelly; Peter J Mogayzel
Journal:  BMC Pulm Med       Date:  2011-09-06       Impact factor: 3.317

4.  Ventilation inhomogeneities in children with congenital thoracic malformations.

Authors:  Payal H Mandaliya; Matthew Morten; Rajendra Kumar; Alan James; Aniruddh Deshpande; Vanessa E Murphy; Peter G Gibson; Bruce Whitehead; Paul Robinson; Joerg Mattes
Journal:  BMC Pulm Med       Date:  2015-03-25       Impact factor: 3.317

5.  Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices.

Authors:  Daiki Hira; Hiroyoshi Koide; Shigemi Nakamura; Toyoko Okada; Kazunori Ishizeki; Masafumi Yamaguchi; Setsuko Koshiyama; Tetsuya Oguma; Kayoko Ito; Saori Funayama; Yuko Komase; Shin-Ya Morita; Kohshi Nishiguchi; Yasutaka Nakano; Tomohiro Terada
Journal:  PLoS One       Date:  2018-02-20       Impact factor: 3.240

6.  Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator.

Authors:  Magnus Schou; Pär Ewing; Zsolt Cselenyi; Markus Fridén; Akihiro Takano; Christer Halldin; Lars Farde
Journal:  EJNMMI Res       Date:  2019-01-29       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.